Open For Collaboration:An Academic Platform For Drug Discovery And Development At Scilifelab
Authors: Per I. Arvidsson, Kristian Sandberg, Karin Forsberg-Nilsson
Abstract:
Sweden, a nation with a population of only 10 million, has a rich legacy of fostering the growth of its pharmaceutical industry and research. Notable companies like Kabi, which was the first to license Genentech's recombinant DNA technology (later overtaken by Pharmacia, subsequently merging with Upjohn and eventually closing as part of Pfizer), along with Hässle (acquired by Astra) and Astra (merged with Zeneca to form AstraZeneca), have contributed to Sweden's pharmaceutical success. Despite the closure of three major global pharma research sites in the country, pharmaceuticals continue to be a significant export for Sweden, with a substantial portion originating from AstraZeneca's manufacturing plant in Södertälje.
The industry's reorganization aftermath has led to the emergence of several regions with robust capabilities for life science innovation. Key geographical areas include Stockholm/Uppsala, housing 51% of life science companies, Malmö/Lund with 19%, and Göteborg with 17%. These regions serve as thriving hubs for numerous smaller biotech companies, with Medivir, located outside Stockholm, currently being the largest among them [1].
Citation: Per I. Arvidsson, Kristian Sandberg, Karin Forsberg-Nilsson Open For Collaboration: An Academic Platform For Drug Discovery And Development At Scilifelab http://dx.doi.org/10.1016/j.drudis.2016.06.026
Available online: 29 June 2016
Copyright: © 2016 The Authors. Published by Elsevier Ltd This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/).
